Arthur Klausner Insider Profile
11 Followers
Arthur Klausner, Director at Monopar Therapeutics Inc, holds 8.76K shares in Monopar Therapeutics Inc (Ticker: MNPR), holds 18.57K shares in Santarus (Ticker: SNTS). Most recently, Arthur Klausner Sold ― shares of Monopar Therapeutics Inc on Dec 19, 2025 for an estimated value of $343.89K.
Arthur Klausner has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Arthur Klausner's holdings
Insider Roles
Director
Roles that Arthur Klausner holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Arthur Klausner
Arthur Klausner's Trading History
Monopar Therapeutics Inc
Dec 19, 2025
Director
Informative Sell
343.89K
$990.46K
Santarus
―
―
―
―
List of latest transactions for each holding click on a transaction to see Arthur Klausner's performance on stock
You May Also Like
Arthur Klausner insider profile FAQ
What is the percentage of profitable transactions made by Arthur Klausner?
The percentage of profitable transactions made by Arthur Klausner is ―.
What is the average return per transaction made by Arthur Klausner?
The average return per transaction made by Arthur Klausner is ―.
What stocks does Arthur Klausner hold?
Arthur Klausner holds: MNPR, SNTS stocks.
What was Arthur Klausner’s latest transaction?
Arthur Klausner latest transaction was an Informative Sell of $343.89K.
What was Arthur Klausner's most profitable transaction?
Arthur Klausner’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Arthur Klausner's role in Monopar Therapeutics Inc?
Arthur Klausner's role in Monopar Therapeutics Inc is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.